ATS Stat

HomeATS Stat ▶ Stat Oct. 27, 2021
Stat Oct. 27, 2021

One Week Left! Submit Your Abstracts for ATS 2022!

Join us for the ATS 2022 International Conference in San Francisco! Abstracts can report on basic, translational, and clinical science research; epidemiologic, social, biobehavioral, and psychosocial investigations; or educational and quality improvement projects.
If you would like guidance as you begin the submission process, please see our resources:

View the full submission criteria, and begin yours today!

Deadline: 5 p.m. ET, Nov. 3, 2021


ATS President’s Message: Equity Matters

I have the honor of representing ATS, along with our CEO Karen Collishaw, in the new “Equity Matters” program, an 18-month initiative organized by the Council of Medical Specialty Societies and the Accreditation Council for Graduate Medical Education. The Equity Matters program centers around continuous learning and process improvement in the areas of diversity, equity, and inclusion (DEI) and anti-racism practices.  

Read the full President’s Message now!


Scientific & Mini Symposia 2021 Program

Please join us for our upcoming Scientific & Mini Symposia 2021 Program! Sessions are 90 minutes long and are open access to all who are interested.

  • SRN 143 - Scientific Symposia, “Controversies in Sleep Apnea Pathophysiology Debate”

When: 5 p.m. ET, Oct. 27, 2021
Register here!

  • AII 1350 - Scientific Symposia, “Beyond Alum and Capsular Polysaccharides: Novel Vaccine Approaches for Pulmonary Infection”

When: 12 p.m. ET, Nov. 4, 2021
Register here!

  • PEDS - Mini Symposia, “Leaving a Mark – Intrinsic and Extrinsic Regulators of Asthma and Lung Function”

When:  5 p.m. ET, Nov. 7, 2021
Register here!


Upcoming Events

Industry Innovations, “Managing COVID-19 in Hospitalized Patients: Current Treatment Landscape”

Key data from pivotal clinical trials, including time to recovery, mortality, and safety, will be discussed, providing the evidence base for their use in hospitalized COVID-19 patients.

When: 6:30 p.m. ET, Oct. 27, 2021
Register now.

Sponsored by Eli Lilly and Company


The Children’s Interstitial and Diffuse Lung Disease Research Network (chILD-RN) Special Interest Group Virtual Meeting 2021

When: 12 p.m. ET, Oct. 29, 2021
Register now!


Industry Innovations, "REPLACE: (Riociguat rEplacing PDE-5i therapy evaLuated Against Continued PDE-5i thErapy): A Look at Phase IV Study Data" 

When: 12 p.m. Nov. 1, 2021
Register now.

Sponsored by Bayer Healthcare.


Industry Innovations, “Prone Positioning: What’s New?”

This program will provide a comprehensive look at proning including the latest evidence and practical applications of proning patients on various levels of respiratory support. 

When: 12 p.m. ET, Nov. 8, 2021
Register now.

Sponsored by Fisher & Paykel Healthcare 


EGPA: Facilitating Prompt Recognition and Optimal Treatment

"EGPA: Facilitating Prompt Recognition and Optimal Treatment," a one-hour activity led by three EGPA experts, will address the most current information on the diagnosis, treatment initiation, and long-term monitoring of this rare eosinophilic disorder. Full CME information is available here.

Expires: Nov. 13, 2021
Register and get started now!

Supported by an educational grant from GlaxoSmithKline.


PINE Series: COVID pneumonia

Hosted by the Assembly on Pulmonary Infections (PI-TB) Early Career Professionals Working Group, “Pulmonary Infection Network of Experts” (PINE). PINE seeks to highlight a different pulmonary infection each month in an interactive format.

When: 4 p.m. ET, Nov. 17, 2021
Register now.



PF-ILD, IPF, and CTD-ILD Primers Available!

The ATS ILD Education Center was developed by a panel of ILD experts in who believe improving patient outcomes begins with an accurate, early diagnosis. This educational site features tools and resources for practicing pulmonologists, general practitioners, radiologists, pathologists, and rheumatologists, designed to help improve patient outcomes with an accurate and early diagnosis.

Check out our newest resources:

Supported by Boehringer Ingelheim Pharmaceuticals, Inc